Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48.

Metabolic screening in children receiving antipsychotic drug treatment.

Author information

  • 1Department of Health Systems, Management,and Policy, Colorado School of Public Health, University of Colorado at Denver, Aurora, Colorado 80045, USA. Elaine.Morrato@ucdenver.edu

Erratum in

  • Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

Abstract

OBJECTIVES:

To estimate metabolic screening rates, predictors of screening, and incidence of metabolic disturbances in children initiating second-generation antipsychotic (SGA) drug treatment.

DESIGN:

A retrospective, new-user cohort study (between July 1, 2004, and June 30, 2006) using Medicaid claims data.

SETTINGS:

California, Missouri, and Oregon.

PATIENTS:

A total of 5370 children (aged 6-17 years) without diabetes mellitus taking SGA drugs and 15,000 children without diabetes taking albuterol (control individuals) [corrected] but no SGA drugs.

INTERVENTION:

Findings 1 year after recommendations from the American Diabetes Association and American Psychiatric Association called for metabolic screening of patients receiving SGA drugs.

OUTCOME MEASURES:

Serum glucose and lipid testing, 6-month incidence of diabetes, and dyslipidemia disturbances.

RESULTS:

Glucose screening was performed in 1699 (31.6% [95% confidence interval (CI), 30.4%-32.9%]) SGA-treated children vs 1891 (12.6% [12.1%-13.2%]) control individuals. Lipid testing was performed in 720 (13.4% [95% CI, 12.5%-14.4%]) SGA-treated children vs 458 (3.1% [2.8%-3.3%]) controls. In multivariate logistic regression analysis, children with serious and/or multiple psychiatric diagnoses and those who used health care services more intensively were more likely to receive metabolic screening. The case incidence of glucose and lipid disorders was higher in SGA-treated vs albuterol-treated children (8.9 per 1000 children [95% CI, 6.6%-11.8%] vs 4.9 per 1000 children [3.9%-6.2%]; and 9.7 per 1000 children [95% CI, 7.2%-12.7%] vs 4.6 per 1000 children [95% CI, 3.6%-5.8%], respectively).

CONCLUSION:

Most children starting treatment with SGA medications in this public sector sample did not receive recommended glucose and lipid screening.

PMID:
20368487
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk